Captor Therapeutics Spolka Akcyjna

BST:60Q Stock Report

Market Cap: €51.9m

Captor Therapeutics Spolka Akcyjna Future Growth

Future criteria checks 6/6

Captor Therapeutics Spolka Akcyjna is forecast to grow earnings and revenue by 71.9% and 30.2% per annum respectively. EPS is expected to grow by 57% per annum. Return on equity is forecast to be 104.1% in 3 years.

Key information

71.9%

Earnings growth rate

57.0%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate30.2%
Future return on equity104.1%
Analyst coverage

Low

Last updated25 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:60Q - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202650-186-62
12/31/2025654-2432
12/31/202421-44-52-353
9/30/202419-41-41-41N/A
6/30/202419-47-40-38N/A
3/31/202416-66-58-55N/A
12/31/202313-71-55-52N/A
9/30/202313-66-40-37N/A
6/30/202311-58-43-41N/A
3/31/202310-39-26-25N/A
12/31/20229-36-24-23N/A
9/30/20225-40-32-26N/A
6/30/20225-41-32-27N/A
3/31/20225-38-29-24N/A
12/31/20214-33-34-28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 60Q is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 60Q is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 60Q is expected to become profitable in the next 3 years.

Revenue vs Market: 60Q's revenue (30.2% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 60Q's revenue (30.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 60Q's Return on Equity is forecast to be very high in 3 years time (104.1%).


Discover growth companies